dapsone has been researched along with Creutzfeldt-Jakob Syndrome in 1 studies
Creutzfeldt-Jakob Syndrome: A rare transmissible encephalopathy most prevalent between the ages of 50 and 70 years. Affected individuals may present with sleep disturbances, personality changes, ATAXIA; APHASIA, visual loss, weakness, muscle atrophy, MYOCLONUS, progressive dementia, and death within one year of disease onset. A familial form exhibiting autosomal dominant inheritance and a new variant CJD (potentially associated with ENCEPHALOPATHY, BOVINE SPONGIFORM) have been described. Pathological features include prominent cerebellar and cerebral cortical spongiform degeneration and the presence of PRIONS. (From N Engl J Med, 1998 Dec 31;339(27))
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Manuelidis, L | 1 |
| Fritch, W | 1 |
| Zaitsev, I | 1 |
1 other study available for dapsone and Creutzfeldt-Jakob Syndrome
| Article | Year |
|---|---|
Dapsone to delay symptoms in Creutzfeldt-Jakob disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Creutzfeldt-Jakob Syndrome; Dapsone; Disease Progr | 1998 |